Related Experiment Video
Updated: Aug 8, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid
Jessica S Ross1, Jake Lee1, Eduardo Ortiz2
1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Introduction:
Pulmonary carcinoid (PC) is a rare, well-differentiated neuroendocrine tumor of the lung. In patients with metastatic disease, systemic therapies typically have low response rates, and long-term survival is poor. PC frequently expresses DLL3, but whether they respond to the DLL3-targeted bispecific T-cell engager tarlatamab is unknown.
Methods:
We analyzed 11 patients with DLL3-high PC treated with tarlatamab at the Memorial Sloan Kettering Cancer Center. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors version 1.1.
Results:
Response rate was eight of 11 (73%), including one patient with central nervous system-only disease, and the disease control rate was 11 of 11 (100%). All patients experienced a reduction in their measurable disease. One patient had progressed at the time of data cutoff, and the median progression-free survival was not reached. Cytokine release syndrome (CRS) occurred in cycle 1 in nine of 11 patients (82%), including two with grade 3 CRS.
Conclusions:
Tarlatamab reported a high response rate in PC. CRS was common. Tarlatamab is a promising treatment option for patients with PC.
Insights
Tarlatamab shows high response rates in pulmonary carcinoid (PC) patients, a rare lung cancer. This DLL3-targeted therapy offers a promising new treatment option for advanced disease, despite common cytokine release syndrome.
Area of Science:
- Oncology
- Pulmonary Medicine
- Immunotherapy
Background:
- Pulmonary carcinoid (PC) is a rare, well-differentiated neuroendocrine lung tumor with poor prognosis in metastatic stages.
- Current systemic therapies for metastatic PC exhibit limited efficacy and low response rates.
- PC tumors often express DLL3, a potential therapeutic target.
Purpose of the Study:
- To evaluate the efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in patients with DLL3-high pulmonary carcinoid.
- To assess the response rate and disease control in this patient population.
Main Methods:
- Retrospective analysis of 11 patients with DLL3-high PC treated with tarlatamab.
- Tumor response evaluated using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1).
Main Results:
- Tarlatamab demonstrated a high objective response rate (ORR) of 73% (8/11 patients), with 100% disease control (11/11 patients).
- All patients achieved measurable disease reduction; median progression-free survival was not reached at data cutoff.
- Cytokine release syndrome (CRS) occurred in 82% (9/11) of patients, with 2 cases of Grade 3 CRS.
Conclusions:
- Tarlatamab exhibits a significant response rate in pulmonary carcinoid patients.
- While CRS is a common adverse event, tarlatamab represents a promising therapeutic strategy for PC.
- Further investigation is warranted for this DLL3-targeted therapy in neuroendocrine lung tumors.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)